Seven patients with metastatic breast cancer and HER2-positive (n=5) or negative (n=2) In-ABY-025 imaging.
This research was originally published in the Journal of Nuclear Medicine. The analysis of HER2 expression is usually based on the surgical specimen of the primary tumor or, in case of neo-adjuvant therapy or inoperable disease, on biopsies from the tumor(11).
The pathological analysis includes immunohistochemistry (IHC) and in some cases in situ hybridization (FISH). Therapy for patients with disseminated disease is often based on histopathological classification of the primary tumor and not of the metastases. Disparities in HER2 expression of primary breast cancer and metastases have been reported. Meta-analysis of 26 studies including 2520 patients revealed discordance in HER2-expression between the primary tumor and local lymph node metastases in the range of 2.4-7.2% and discordance to distant metastases in the range of 6.9-18.6% and an absolute variation for all studies in the range of 0-40%(12). A recent symposium publication, including 2845 patients, reported absolute variations in the same range(13). Another recent study on 182 patients, with 28% discordance, indicated that patients with loss of HER2-expression in metastases had shorter overall survival than patients with unchanged expression(14).
The biopsy procedure can be inconvenient or even harmful for the patient, demanding lesions of suitable size and carries the risk of sampling errors. Heterogeneity of HER2-expression within lesions and also differences in expression between lesions in the same patient further limit the use of biopsies for correct diagnosis. Thus, improved methods for determining the HER2-status in patients with metastatic breast cancer are needed to optimize treatment regimes. One approach is molecular imaging using a radiolabeled tracer targeting HER2.
Molecular imaging allows whole body detection of aberrant gene expression (i.e. ABY-025, used in the present clinical study, is a second generation Affibody molecule with improved biochemical and biophysical characteristics, designed by protein engineering using an iterative approach of changing 11 amino acids (about 20% of the molecule) outside the HER2 binding region (18, 27) .
In this first-in-human study with 111 In-ABY-025 SPECT/CT we evaluate safety and tolerability and explore the uptake in tumor metastases and background uptake in normal organs.
It was also of interest to study the ability of 111 In-ABY-025 to discriminate between HER2-positive and negative metastases.
PATIENTS AND METHODS

Patients
Seven female patients (mean age 61.3 years, range 46-70) on treatment for recurrent metastatic breast cancer were enrolled into the study (Table 1) . Five of the patients were diagnosed with HER2-positive primary tumors and two had HER2-negative tumors and served as controls.
Inclusion and exclusion criteria
Protocol criteria for inclusion and exclusion are detailed in Supplementary material.
Briefly, patients with diagnosis of metastatic breast cancer and known HER2 classification of primary tumor (HER2-positive: score of 3+ using HercepTest or FISH-positive, score 2+ with HercepTest and FISH-positive; HER2-negative: score 0 or 1+ using HercepTest, or score 2+ but FISH-negative) were potential participants. On-going treatment was not an exclusion criteria.
Approvals
The Swedish Medical Products Agency, the regional ethics committee in Uppsala and the radiation protection ethics committee in Uppsala approved the study. Written informed consent was obtained from all participants. The study was registered as a clinical trial with the identifiers EudraCT 210-021078-12 and NCT01216033.
Patient characterization and safety assessment
In accordance with the study protocol all patients underwent physical examination at least 7 days before, immediately before and 7 days after injection of 111 In-ABY-025. Standard clinical chemistry of blood and urine was investigated according to approved protocol. Possible adverse effects were investigated orally and with written patient questionnaires before and after
111
In-ABY-025 injection (day 0) and 1, 7, 21 and 42 days later. Blood samples for determination of shed serum HER2 were taken immediately before injection, and the assays (ADIVA Centaur HER2/neu-Test, Siemens Healthcare Diagnostics) were thereafter performed at Laboratory Limbach, Heidelberg, Germany. Presence of anti-ABY-025 antibodies was measured in samples taken before, 21 and 42 days after injections, using an ELISA assay developed by Affibody AB and performed at Clinical Chemistry and Pharmacology Laboratory at Uppsala University Hospital, Sweden.
F-FDG PET/CT and other clinical imaging
The metastatic status of patients was known prior to inclusion based on conventional imaging. quantitative imaging were applied. The acquired data were evaluated using Hybrid Viewer (Hermes Medical, Sweden) and Advanced Workstation (GE Healthcare). For each lesion detected by PET/CT, the maximum standard uptake value (SUV) was noted. The volume of each tumor lesion was calculated by a thresholding technique including all voxels with equal or more than 42% of maximum SUV. Additionally, MR, ultrasound or contrast enhanced CT were applied when needed for biopsies and further patient management.
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In-ABY-025 imaging 111 In-ABY-025 was prepared essentially as described earlier(18). GMP grade ABY-025 was provided by Affibody AB in vials containing 100 µg. ABY-025 was labeled with 111 In at the Department of Nuclear Medicine, Uppsala University Hospital. Patients were not required to fast before injection.
In-ABY-025, about 100 µg, with a mean activity of 142.6 MBq (range 131-154), was injected intravenously. At 4, 24 and 48 hours post injection, whole body planar scans were performed followed by SPECT/CT (Infinia Hawkeye 4, GE Healthcare) over individually selected areas of special interest, defined by findings in an initial planar scan (anterior and posterior) after about 30 min, as well as 18 F-FDG PET/CT. Low dose CT scans without contrast enhancement were acquired for attenuation correction and anatomical correlation. SPECT data were reconstructed with CT-based attenuation correction into a 128x128 matrix using an iterative reconstruction algorithm.
Blood samples and biopsies
Blood samples were collected at 10 and 30 min, 2, 6, 24, 48 hours and 7 days after injection to determine blood clearance kinetics. Following SPECT/CT results, optional biopsies were taken from suitable and clinically relevant lesions. In two patients (patient 1 and 2) metastases were surgically removed after the study. Biopsies were analyzed by IHC (HercepTest TM , DAKO) to verify the HER2 status.
Statistical analysis
Quotients between the 24/4 or 48/4 hours uptake of 111 In-ABY-025 were calculated and 108 metastatic lesions larger than 1.5 mL, as measured by FDG-PET/CT, were included in further analysis. The significance in difference between 4 and 24 hours uptake values in HER2 positive metastases was analyzed using the non-parametric Kruskal-Wallis one-way analysis of variance (ANOVA). The significance in difference between quotient values and SUV for HER2-positive and HER2-negative metastases was analyzed using the non-parametric Mann-Whitney U-test. A two-sided p-value less than 0.05 was considered significant.
Supplementary material
Information on protocol inclusion and exclusion criteria, patient medical history, blood kinetics determination,
111
In-ABY-025 imaging of normal tissue uptake, dosimetry, the dual time-point analysis, metastatic SUV measurements and biopsy data (including IHC and evaluation criteria) are provided in Supplementary material.
RESULTS
Safety assessment
The administration of 111 In-ABY-025 was well tolerated. No clinically significant changes in laboratory evaluations or in vital signs were recorded. No anti-ABY-025 specific antibodies could be detected in any of the patients 3 and 6 weeks after exposure (data not shown).
Pharmacokinetics, biodistribution and dosimetry
Blood kinetics of 111
In-ABY-025 and uptake in kidney, liver and spleen are presented in Table 2 (and Table S1 in Supplementary material). Clearance of 111 In from blood was biphasic with first half-life 2.9±0.5 hours and second half-life 27±5 hours. In normal organs, the highest uptake was observed in the kidney followed by liver and spleen. Uptake in salivary glands and bowels was also visualized. No correlation was found between any organ uptake and shed serum HER2 (8.8 -56 µg/L; the upper limit of normal is 15 µg/L, Table 1 ). The normal organ receiving the highest radiation dose was the liver, followed by the kidneys and spleen at 0.068±0.025, 0.020±0.006, and 0.005±0.002 mSv/MBq, respectively. The effective radiation dose for the patients was 0.15±0.02 mSv/MBq (21 mSv per patient).
Uptake in metastases
In the HER2-positive patients, large metastases (>> 1cm) identified by In-ABY-025 SPECT showed low or no uptake in the FDG-defined lesions and the HER2-negative status of biopsies from these lesions was confirmed by IHC ( Figure 2 and Supplementary material). Patients 5 and 6 had HER2 negative primary tumors and the uptake of 111 In-ABY-025 in their metastases was of low contrast and HER2-negative status was verified by IHC on biopsies from patient 5 (patient 6 refused biopsy).
Discrimination between metastases with high and low HER2 expression
The quantitative In-ABY-025 is feasible and might be valuable for selection of patients that may, or may not, benefit from HER2-targeted therapies, hence improving treatment utility and cost effectiveness.
ACKNOWLEDGEMENT
We thank the Swedish Cancer Society for financial support (contracts 110565 and 120415), the staff at Department of Nuclear Medicine, Uppsala University Hospital and research nurse Jessica Barrefjord, Department of Oncology, Radiology and Radiation Sciences, Uppsala University, Sweden, for administration and patient care. In-ABY-025 uptake was visible on SPECT images of a few small lesions defined as metastases by 18 F-FDG PET/CT in patients 1, 2, 3 and 7. Due to the sensitivity limit of SPECT it is not known whether these few were HER2-positive or HER2-negative.
** The
111 In-ABY-025 uptake seen in 18 F-FDG PET/CT defined metastases from patients 4, 5 and 6 gave low signals from large metastases and no signals from small metastases. The reason for 111 In-ABY-025 SPECT signals in some large metastases although low HER2 expression in IHC is discussed in the text. Figures   Fig 1. Examples of imaging of HER2-expression in breast cancer metastases using 
More than 10% of the tumor cells in the primary tumor had strong circumferential HER2 staining of their entire cell membrane and therefore the patient was declared HER2-positive. (B) shows the 18 F-FDG PET/CT scan 5 days prior to SPECT. In total, 71 metastases were detected (Table 3 ). (C) shows the HER2 scan 4 hours after injection of 111 In-ABY-025. No HER2-expressing metastases could be detected in this scan but three metastases with low HER2-expression could be detected in SPECT/CT sections after 4 hours and some more after 24 hours (Table 3 ). However the 24/4 hour quotients indicated HER2 negative metastases in all these metastases. This was verified by IHC analysis of biopsies. Column (D) shows examples of IHC analyzes of three different metastases; top photo: thyroid metastasis that scored 0, middle photo: calcified thyroid metastasis that scored 0 and bottom: bone metastasis that scored 1+. The bars in the IHC-images correspond to 50 μm. She had been treated with anthracyclines and capecitabine and was on paclitaxel when enrolled in this trial.
Patient 7 was a 57 year old postmenopausal Caucasian woman diagnosed with left sided breast cancer 5 years before entering this study. She had eleven positive lymph nodes and the primary tumor was ER-and PgR-positive and HER2-positive (3+). After surgery she received adjuvant chemotherapy followed by trastuzumab and tamoxifen. Three years later she was diagnosed with bone metastases and treated with docetaxel and trastuzumab. Endocrine therapy was then used for ten months and followed by five lines of chemotherapy with concomitant trastuzumab or lapatinib for about 1.5 years. At the time of enrolment in the study she was treated with carboplatin and trastuzumab.
Blood kinetics determination
Blood samples were collected at 10 and 30 min, 2, 6, 24, 48 hours and 7 days after injection to determine blood clearance kinetics. The vials for the blood samples were weighted with a 0.1 mg accuracy scale (Mettler PJ300). The amount of radioactivity in the vial was then measured using an automatic well counter (Wizard 3 (1480) from PerkinElmer). Results (%ID/g) with mean values and standard deviations are given in Table 2 in the manuscript and individual patient values in Table S1 below.
F-FDG-PET/CT imaging
The method for 18 F-FDG-PET/CT scanning is described in the manuscript. These scans were additional to other clinical diagnostic procedures. Approximately150 of 249 lesions identified with 18 F-FDG-PET/CT were also detectable with 111 In-ABY-025 and considered to be metastases. Lesions seen with 18 F-FDG-PET/CT but not seen with 111 In-ABY-025 are probably metastases with low or no HER2-expression. It is also possible that they were HER2-positive but so small that the lower resolution and sensitivity of 111 In-gamma camera imaging technology prevented them from being detected. A few lesions identified with PET were classified as nontumor, based on all radiological and clinical information, none of these were SPECT-positive.
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In-ABY-025 imaging and normal tissue uptake
The patients underwent an initial planar (anterior and posterior) whole body planar scan at scans at 4, 24 and 48 hours after injection of 111 In-ABY-025. Planar images were corrected for attenuation using a transmission scan with a 57
Co flood source. Regions of interest were drawn over metastases and whole-body in the planar images to obtain the whole organ activities. In the attenuation-corrected SPECT images, 4 ml volumes of interest were drawn over metastases, liver, spleen and kidneys, giving organ activity concentrations. These were, for the normal organs, multiplied with standardized normal organ weights to obtain the whole organ activities.
Integrated activity for the normal organs was calculated by a single-exponential fit to the 24 and 48 hours data points. Integrated activity for remainder of the body was calculated as whole body minus defined source organs. Results (%ID/g) with mean values and standard deviations for kidneys, liver and spleen are given in Table 2 in the manuscript and the values for individual patients in Table S1 below. 
Dosimetry
Absorbed radiation doses were estimated using OLINDA/EXM 1.1 
The dual time-point analysis
Analysis was performed to evaluate the lesion uptake pattern over time. Activity in the metastases was measured using small volumes of interest from SPECT images corrected for attenuation and decay at all three time points. Analyses were performed on all lesions detected by FDG-PET/CT and SPECT/CT with subanalyses performed on the subject level (average of all lesions) and for biopsy-verified lesions. The average lesion uptake continued to increase from 4 to 24 hours in HER2-positive cases and decreased in HER2-negative cases (p<0.05 for both).
These findings imply that relative to the early deposition at 4 hours, uptake continues to increase (by 21-43%) in lesions that are HER2-positive, differentiating this group of subjects with no overlap from the HER2-negative cases in which lesion uptake decreases (3-10%) (p<0.05, Mann Whitney U-test). Thus, serial imaging using 111 In-ABY-025 SPECT at 4 hours and 24 hours appears to provide a diagnostic opportunity for differentiating HER2-positive from HER2-negative patients.
Analyzed metastases and biopsies
The NCCN guidelines (http://www.nccn.org/patients/guidelines/breast/) and the recommendations of the Swedish Breast Cancer Group (national guideline for treatment of breast cancer, written in Swedish) were considered. Decision about when a biopsy should be taken was decided by the responsible physician with patient consent. The Swedish Medical Products Agency, the regional ethics committee and the radiation protection ethics committee approved this procedure.
Detected lesions were considered to be metastases by two specialists in nuclear medicine. 
6
No biopsy taken -Negative NA
7
CT-guided biopsy from sacral (S1) bone metastasis 3+ Positive 8.8
Note: All bone biopsies were performed with use of 14G Bonopty bone biopsy system (Apriomed, Uppsala, Sweden). * No visible uptake compared to background. ** High value due to proximity to the kidney.
A possible single time-point assay
As a complement to the "dual time-point" analysis, described in the manuscript and above,
we calculated a few examples for a possible future "single time-point" assay. We used data 24 hours after injection, visually regarded as the highest image quality. SPECT-based Standardized Uptake Values, SUV, were calculated as SUV = ROI counts per mL x calibration factor x body weight in grams / injected dose.
A calibration factor for conversion of counts per mL to concentration was applied by repeated measurements of a 100 ml sphere containing a know amount of 111 In and positioned inside a thorax phantom. The obtained 24 hours SUV for the biopsied metastases are shown in Table S3 .
Note that the SUV for patient 2 (brain metastasis scored 3+) was not very different from the SUV for patient 5 (lymph node metastasis scored 1+), i.e. 3.9 and 2.7, respectively. No calibration factor with a head phantom was available, which could have altered the SUV value.
Note also that the 24 hours SUV for patient 3 (adrenal metastases) was extremely high, probably due to signal spillover from the adjacent kidney. The adrenal metastasis could anyhow be easily distinguished from the kidney, as seen in Figure 1 in the manuscript.
Scanner resolution and scatter correction with SPECT/CT are less optimal than for PET/CT, which will affect the accuracy of measurements. In an attempt to reduce the impact of partial volume effects, we also performed a SPECT SUV-analysis for the largest metastases with diameter >3 cm, HER2-positive (n=9) and HER2-negative (n=8). One to 3 metastases were included per patient. The result is shown in Figure S2 and there was a significant difference in mean SUV (9.8±3.1 vs. 2.3±1.0, p<0.001). The data indicates that SUV at 24h reflects HER2 status. However, the "single time-point" assay is technically less applicable for routine clinical SPECT than the "dual time-point" assay (24/4 hour quotients). Furthermore, a quotient uptake approach is less affected by partial volume effects than are static concentration measurements. It
is of course necessary to analyze and compare the different assays including more patients, which was beyond the scope of this formalized Phase I study. Most likely, a SUV-based "single time-point" assay probably can be used if a well calibrated PET scanning using a positron emitter is applied (e.g. 68 Ga-or 18 F-labeled ABY-025). biopsy) with SUV 34.9 was considered a measurement outlier due to signal spillover from adjacent kidney tissue and was removed in the analysis.
